| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Exemestane (JAN/USP/INN); Aromasin (TN) | ||||||||||||
| Product | AROMASIN (Pharmacia & Upjohn Company LLC) | ||||||||||||
| Generic | EXEMESTANE (A-S Medication Solutions), EXEMESTANE (Alvogen), EXEMESTANE (Amneal Pharmaceuticals LLC), EXEMESTANE (Aurobindo Pharma Limited), EXEMESTANE (Breckenridge Pharmaceutical), EXEMESTANE (Bryant Ranch Prepack), EXEMESTANE (Cadila Healthcare Limited), EXEMESTANE (Cipla USA), EXEMESTANE (Eirgen Pharma), EXEMESTANE (Florida Pharmaceutical Products), EXEMESTANE (Greenstone LLC), EXEMESTANE (Hikma Pharmaceuticals USA), EXEMESTANE (Mylan Pharmaceuticals), EXEMESTANE (Upsher-Smith Laboratories), EXEMESTANE (Zydus Pharmaceuticals (USA)) | ||||||||||||
| Formula | C20H24O2 | ||||||||||||
| Exact mass | 296.1776 | ||||||||||||
| Mol weight | 296.4034 | ||||||||||||
| Structure |  | ||||||||||||
| Simcomp | |||||||||||||
| Class | Antineoplastic DG01596 Aromatase inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antineoplastic, Estrogen biosynthesis inhibitor | ||||||||||||
| Disease | Breast cancer, postmenopausal (ER-positive) [DS:H00031] | ||||||||||||
| Comment | Aromatase inhibitor | ||||||||||||
| Target | CYP19A1 (ARO) [HSA:1588] [KO:K07434] | ||||||||||||
| Pathway |
| ||||||||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] | ||||||||||||
| Interaction | |||||||||||||
| Structure map |
| ||||||||||||
| Other map |
| ||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L02 ENDOCRINE THERAPY L02B HORMONE ANTAGONISTS AND RELATED AGENTS L02BG Aromatase inhibitors L02BG06 Exemestane D00963 Exemestane (JAN/USP/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Aromatase Inhibitors, 3rd Generation Exemestane D00963 Exemestane (JAN/USP/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D00963 Exemestane (JAN/USP/INN) Drug groups [BR:br08330] Antineoplastic DG01596 Aromatase inhibitor D00963 Exemestane Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D00963 Exemestane Drug classes [BR:br08332] Antineoplastic DG01596 Aromatase inhibitor D00963 Exemestane Target-based classification of drugs [BR:br08310] Enzymes Oxidoreductases (EC1) Cytochrome P450 CYP19A1 (ARO) D00963 Exemestane (JAN/USP/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D00963 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D00963 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D00963 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D00963 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D00963 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 22 1 C2x C 12.2500 -16.2400 2 C5x C 12.2500 -17.6400 3 C2x C 13.4624 -18.3400 4 C2y C 14.6749 -17.6400 5 C1z C 14.6749 -16.2400 6 C2x C 13.4624 -15.5400 7 C2y C 15.8873 -18.3400 8 C1x C 17.0997 -17.6400 9 C1y C 17.0997 -16.2400 10 C1y C 15.8873 -15.5400 11 C1y C 18.3122 -15.5400 12 C1z C 18.3122 -14.1400 13 C1x C 17.0997 -13.4400 14 C1x C 15.8873 -14.1400 15 C1x C 20.7370 -15.5400 16 C1x C 20.7370 -14.1400 17 C5x C 19.5246 -13.4400 18 O5x O 19.5246 -12.0400 19 O5x O 11.0376 -18.3400 20 C2a C 15.8873 -19.7400 21 C1a C 14.6749 -14.8400 22 C1a C 18.3122 -12.7400 BOND 25 1 1 2 1 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 1 6 1 6 2 7 4 7 1 8 7 8 1 9 8 9 1 10 9 10 1 11 5 10 1 12 9 11 1 13 11 12 1 14 12 13 1 15 13 14 1 16 10 14 1 17 11 15 1 18 15 16 1 19 16 17 1 20 12 17 1 21 17 18 2 22 2 19 2 23 7 20 2 24 5 21 1 #Up 25 12 22 1 #Up |